Ki20227

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β) . Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1].

Product Specifications

CAS Number

[623142-96-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Fms; c-Kit; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Ki20227.html

Concentration

10mM

Purity

99.51

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C=C1OC)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC(C)C4=NC=CS4

Molecular Formula

C24H24N4O5S

Molecular Weight

480.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5 (11) :2634-43.|[2]Boru Hou, et al. Ki20227 influences the morphology of microglia and neurons through inhibition of CSF1R during global ischemia. Int J Clin Exp Pathol. 2016;9 (12) :12459-12469.